Biocon to spend 10% of its annual biopharma revenue on R&D in next fiscal year

02 Feb 2015 Evaluate

Biocon is planning to spend 10 per cent of its annual biopharma revenue on research and development (R&D) in the next fiscal year. The company, which is pursuing R&D in both novel biologics as well as biosimilars (generic versions of biologic drugs), in various stages of trials, had spent around Rs. 131 crore on R&D in the previous fiscal year which was 6 per cent of biopharma sales.

The pharma major has spent Rs 47 crore on R&D in the third quarter of this fiscal, an increase of 124 per cent over the corresponding period of the year-ago period. The firm earned revenues of Rs. 436 crore from its biopharma business during the quarter.

Biocon is India’s largest and Asia’s leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

392.80 4.55 (1.17%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×